Indee Labs GTM brain

Indee Labs sells Hydropore non-viral intracellular delivery technology to researchers engineering immune cell therapies.

category

Cell therapy intracellular delivery

market profile

  • text: Cell therapy developers need to introduce editing payloads while preserving cell quality, and compare microfluidics with electroporation.
  • text: The Hydropore research product is described as research use only; clinical manufacturing requires a separate system and validation.

personas

  • title: Cell therapy discovery scientist
    pains:
    • Introducing CRISPR payloads can damage immune cells or compromise viable yield.
    • Small-volume screening must produce reliable comparisons across candidates.
  • title: Cell therapy process development lead
    pains:
    • Discovery-scale methods may not translate to clinically relevant cell volumes.
    • A research-use tool needs a clear path to qualification before manufacturing use.
  • title: Genome engineering platform lead
    pains:
    • Existing electroporation or viral approaches may constrain the payload, throughput or cell function.
    • Platform selection demands cell-specific comparative data.

icp

  • text: Biopharma cell therapy R&D and process development groups engineering T cells, from biotechnology firms through large pharmaceutical companies.
  • text: Academic and translational immunotherapy labs running gene editing and pooled immune-cell screens; institution size is not specified.

message pillars

  • text: Use a scalable non-viral approach for engineered cell therapy work.
  • text: Deliver multiple payload classes into immune cells.
  • text: Aim for large numbers of cells while preserving function.

objections

  • objection: Can we use this in clinical manufacturing now?
    response: The site describes the current system as research use only; ask for clinical development status, validation and regulatory documentation.
  • objection: Will it outperform our established electroporation process?
    response: Run a representative cell and payload comparison measuring editing, viability, function and throughput.

competitors

  • name: MaxCyte
    why: Provides non-viral flow electroporation for cell engineering.
  • name: Kytopen
    why: Develops cell engineering delivery technologies for cell therapy.
  • name: CellFE
    why: Offers microfluidic intracellular delivery approaches.

influencers

  • name: Ryan Pawell
    url: https://sbir.cancer.gov/commercialization/business/investor-initiatives-0
    why: Founder and CEO identified by the National Cancer Institute.

keywords

  • nonviral cell engineering
  • T cell transfection
  • immune cell gene editing delivery
  • cell therapy manufacturing delivery
  • microfluidic intracellular delivery
  • pooled CRISPR screening

voice

  • technical
  • research-focused
  • future-oriented

signals

  • text: A cell therapy program is scaling CRISPR editing from discovery to process development.
  • text: An immune-cell laboratory is evaluating alternatives to viral delivery or electroporation.

stack

  • microfluidic vortex shedding

pricing

model: unknown

motion

sales_led

channels

  • scientific publications
  • distribution partners
  • newsletter

confidence

medium

Founders

  • name: Ryan Pawell
    title: Founder/CEO
    role: CEO
    bio: My career aim is to use technology to improve health outcomes. See more on my LinkedIn profile.

Back to YC companies